Feed CPRX
CP

Catalyst Pharmaceuticals CPRX NASDAQ · Healthcare · United States

$31.49 -0.02% -$0.01

Market cap
$3.85B
Enterprise value
$3.10B
P/E
17.4x
Forward P/E
-
PEG
0.6x
P/S
6.5x
P/FCF
18.5x
EV/EBITDA
11.1x
ROIC
19.7%
Gross margin
122.0%
Net margin
37.1%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-2.7x
Beta
0.74
Free float
94.4%

About the company

Catalyst Pharmaceuticals, Inc. (CPRX) is an American biopharmaceutical company specializing in research, development, and commercialization of drugs for rare neurological disorders. With activities in biotechnology and pharmacology, Catalyst Pharmaceuticals is a key player in the world of innovative treatment approaches. Their research focuses on discovering new treatment options and therapies for patients with neurological disorders, such as Lambert-Eaton myasthenic syndrome (LEMS). The company aims to provide modern treatment solutions and improve the quality of life for patients with rare diseases. Catalyst Pharmaceuticals is characterized by expertise in pharmacology and neurology. Catalyst Pharmaceuticals, Inc. (CPRX) shares could be suitable for investors looking for an investment opportunity in the biopharmaceutical sector with a company that specializes in innovative treatment approaches and therapies for patients with rare neurological disorders.

Sector

Healthcare

Industry

Biotechnology

CEO

Richard John Daly

Employees

182

Headquarters

Coral Gables

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

  • What speaks for it: Earnings per share grew by 31% a year over the last 3 years.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What speaks for it: Out of every 100 USD of revenue, 37 USD is left as net profit.
  • What speaks for it: It earns 20 USD a year on every 100 USD of invested capital.

Financial health

Can it carry its debt?

  • What speaks for it: It holds more cash than debt: $517.6M against $3.19M.

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy